Hemostemix Inc. (CVE:HEM – Get Free Report) shares were up 20.9% on Thursday . The company traded as high as C$0.29 and last traded at C$0.26. Approximately 1,333,171 shares were traded during trading, an increase of 93% from the average daily volume of 689,390 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Performance
The stock’s fifty day simple moving average is C$0.10 and its two-hundred day simple moving average is C$0.08. The stock has a market capitalization of C$23.96 million, a P/E ratio of -13.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to Evaluate a Stock Before BuyingÂ
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
